SGLT2 inhibitors are associated with lower rates of death for patients with type 2 diabetes

A new class of medication, known as sodium-glucose transporter-2 (SGLT2) inhibitors, is associated with lower rates of death and hospitalisation for heart failure when used to treat patients with type 2 diabetes, both with or without existing cardiovascular disease, and regardless of the specific SGLT2 inhibitor used, according to a study, €œHospitalization for Heart Failure and Death in New Users of SGLT2 Inhibitors in Patients With and Without Cardiovascular Disease€”CVD-REAL Study,€ presented at the American Diabetes Association’s 77th Scientific Sessions at the San Diego Convention Center.  The CVD-REAL study analysed the outcomes of 306,156 patients with type 2 diabetes from five different countries€”the